A Randomized, Double-blind, Placebo-controlled Study of the Dosaging of AMPLIGEN 'Registered trade mark' (POLY I: POLY C12U), an Immunostimulant, in Conjunction With Influenza Vaccination
Phase of Trial: Phase I/II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Influenza virus vaccine; Rintatolimod
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Hemispherx Biopharma
- 05 Feb 2009 Status changed from active, no longer recruiting to completed according to the Australian New Zealand Clinical Trials Registry record.
- 05 Feb 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry record).
- 02 Jun 2008 Status changed from initiated to in progress according to Hemispherx Biopharma.